Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Titan Pharmaceuticals, Inc.    TTNP

TITAN PHARMACEUTICALS, INC.

(TTNP)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Titan Pharmaceuticals: 2Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 04:49pm EDT

SAN FRANCISCO (AP) _ Titan Pharmaceuticals Inc. (TTNP) on Wednesday reported a loss of $5.2 million in its second quarter.

The San Francisco-based company said it had a loss of 38 cents per share.

The specialty pharmaceutical company posted revenue of $502,000 in the period.

In the final minutes of trading on Wednesday, the company's shares hit 70 cents. A year ago, they were trading at $5.40.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TTNP at https://www.zacks.com/ap/TTNP

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on TITAN PHARMACEUTICALS, INC
08/14TITAN PHARMACEUTICALS : 2Q Earnings Snapshot
AQ
08/14TITAN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
08/12TITAN PHARMACEUTICALS : to Release Second Quarter 2019 Financial Results on Augu..
AQ
08/08TITAN PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Unregist..
AQ
06/27TITAN PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
06/05TITAN PHARMACEUTICALS : Partners With Southside to Further Expand Specialty Phar..
AQ
05/16TITAN PHARMACEUTICALS : Reports First Quarter 2019 Financial Results
AQ
05/15TITAN PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condit..
AQ
05/15TITAN PHARMACEUTICALS : 1Q Earnings Snapshot
AQ
05/14TITAN PHARMACEUTICALS : Further Expands Patient Access to Probuphine via Product..
AQ
More news
Financials (USD)
Sales 2019 2,74 M
EBIT 2019 -19,1 M
Net income 2019 -19,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,35x
P/E ratio 2020 -0,78x
Capi. / Sales2019 2,70x
Capi. / Sales2020 0,69x
Capitalization 7,41 M
Chart TITAN PHARMACEUTICALS, INC.
Duration : Period :
Titan Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TITAN PHARMACEUTICALS, INC
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 3
Average target price 9,95  $
Last Close Price 0,47  $
Spread / Highest target 3 298%
Spread / Average Target 2 013%
Spread / Lowest Target 728%
EPS Revisions
Managers
NameTitle
Sunil Bhonsle President, Chief Executive Officer, CFO & Director
Marc Rubin Executive Chairman
Katherine L. Beebe-DeVarney Chief Scientific Officer & Executive VP
M. David MacFarlane Independent Director
Joseph A. Akers Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
TITAN PHARMACEUTICALS, INC.111.17%7
CSL LIMITED22.81%69 599
BIOGEN INC.-24.36%41 986
ALEXION PHARMACEUTICALS13.86%24 450
GRIFOLS25.41%19 155
SAMSUNG BIOLOGICS CO LTD--.--%15 813